The Fort Worth Press - Avenir Wellness Solutions Announces Global Settlement with Ionic Ventures, Eliminating Convertible Debt

USD -
AED 3.672495
AFN 64.000314
ALL 82.253977
AMD 360.509431
ANG 1.790403
AOA 917.499428
ARS 1552.284702
AUD 1.48346
AWG 1.8025
AZN 1.697632
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.778804
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.42811
CDF 2317.999791
CHF 0.838815
CLF 0.025259
CLP 994.110012
CNY 6.66455
CNH 6.665535
COP 3315.05
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.107101
DJF 177.720338
DKK 6.781775
DOP 60.559465
DZD 136.951012
EGP 53.7264
ERN 15
ETB 164.140883
EUR 0.90739
FJD 2.296803
FKP 0.758367
GBP 0.756145
GEL 2.594965
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.501804
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 332.705959
IDR 18268.2
ILS 3.254645
IMP 0.758367
INR 93.45945
IQD 1516.079284
IRR 1925253.999815
ISK 124.130485
JEP 0.758367
JMD 158.919789
JOD 0.709003
JPY 159.245985
KES 129.999866
KGS 87.448984
KHR 4080.072793
KMF 447.497229
KPW 900.00035
KRW 1334.25967
KWD 0.31158
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 55.861384
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.860197
MVR 15.410202
MWK 1734.212921
MXN 18.413075
MYR 4.093596
MZN 63.910227
NAD 16.918528
NGN 1348.670466
NIO 36.80602
NOK 9.59563
NPR 149.481136
NZD 1.81649
OMR 0.384501
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.585016
PKR 276.505202
PLN 3.993785
PYG 6230.864068
QAR 3.64562
RON 4.852297
RSD 106.739941
RUB 82.05711
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.825232
SDG 601.499925
SEK 10.096805
SGD 1.287735
SHP 0.758581
SLE 23.049694
SLL 20969.503664
SOS 571.501363
SRD 37.437951
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.77702
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.414697
TTD 6.771395
TWD 32.925901
TZS 2650.002957
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603599
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 595.208663
XAG 0.021073
XAU 0.000259007303
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 595.208663
XPF 108.509428
YER 236.503646
ZAR 16.92348
ZMK 9001.222553
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.06566
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Avenir Wellness Solutions Announces Global Settlement with Ionic Ventures, Eliminating Convertible Debt
Avenir Wellness Solutions Announces Global Settlement with Ionic Ventures, Eliminating Convertible Debt

Avenir Wellness Solutions Announces Global Settlement with Ionic Ventures, Eliminating Convertible Debt

Avenir Wellness Solutions, Inc. ("Avenir" or the "Company") (OTCQB:AVRW), a proprietary broad platform technology beauty and wellness company, today announced that it has reached a global settlement with its current debt holder Ionic Ventures LLC ("Ionic") to resolve all disputes between the parties.

Text size:

In connection with the settlement, a portion of the outstanding convertible notes with an aggregate carrying value of $8.7 million as of September 30, 2024 will be converted into approximately 8.3 million shares of the Company's common stock at a value of approximately $233 thousand, subject to a leak-out agreement. The remaining amount of convertible notes will be extinguished in exchange for a new 10%/11% two-year note with a principal amount of $2.85 million to be issued to Ionic, inclusive of legal fees Ionic incurred in defending against the lawsuit filed by Avenir in the dispute. The new note will require payment equal to at least 50% of the net proceeds the Company receives if it completes a qualified financing, asset sale or M&A transactions up to the accreted amount of the note, but not later than the two-year anniversary of the issuance of the note. As a result of the extinguishment, the Company is expected to recognize a one-time gain of approximately $5.0 million during the fourth quarter of 2024.

The Company also has withdrawn its lawsuit filed against Ionic in the State of New York in connection with the convertible notes originally issued in 2020. As part of the settlement, Avenir acknowledged that Ionic at all times conducted itself in compliance with the 2020 transaction documents, and the settlement agreement reflects that Ionic admitted to no wrongful conduct in connection with the underlying transaction. For further information on the settlement, please refer to the recently filed Form 8-K.

"Despite building a plant-based wellness and beauty business with very high gross margins the last two full fiscal years, Avenir's total market cap has been severely depressed with the value of the entire company recently totaling less than half of last year's sales. After discussions with our financial advisors, Board of Directors and largest shareholders, we confirmed it is universally believed that the significant outstanding convertible debt is the primary reason why there is a disconnect between Company's market value with its underlying business. Our shareholders were clear that our top priority should be elimination of the convertible debt and the settlement of litigation commenced against Ionic. As such, we have been in active negotiations with Ionic for the past few months and were able to come to terms that we believe are extremely beneficial to the Company and our shareholders," commented Nancy Duitch, Chief Executive Officer of Avenir.

Duitch added, "We are thrilled with this transaction that, together with a bridge financing we are in the process of completing, significantly strengthens our balance sheet and eliminates the overhang our shareholders have cited as the significant obstacle preventing them from increasing their ownership of our stock."

Brendan O'Neil, Ionic's Manager, stated, "From the outset, we denied and we continue to strongly deny the allegations asserted against us in the underlying litigation. Given Avenir's agreement to reimburse us for the attorneys' fees we incurred in defending against those allegations, included in the new note, and its acknowledgement that Ionic complied in all material respects with the controlling agreements relating to the 2020 financing, we concluded that it made good business sense to bring the dispute to a close."

Overall, Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our Nutri-Strip products as well as our unique and proprietary skin care formulations. With 17 patents under our control, the highly positive reviews Seratopical Revolution DNA Complex is receiving, and more new products in development, 2025 is setting up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.

Company Management will be hosting an investor webcast/call to discuss the settlement agreement and provide an update on the Company on Wednesday, December 18, 2024 at 1:00pm PST / 4:00pm EST. Questions may be submitted prior to the webcast by emailing them to [email protected]. To participate in the webcast, please join us at:

https://us06web.zoom.us/j/83688826398?pwd=NzGBQ928B7m34yGgLPBPLI77BY4lGF.1
Meeting ID: 836 8882 6398
Passcode: 797030

One tap mobile
+16694449171,,83688826398#,,,,*797030# US
+13462487799,,83688826398#,,,,*797030# US (Houston)

About Avenir Wellness Solutions, Inc.

Avenir Wellness (OTCQB: AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems. The technology, which is based on fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property by expanding its product lines utilizing the technology. And, as a vertically integrated platform company, Avenir also looks to partner with or license its IP technology to wellness companies worldwide. For more information visit: www.avenirwellness.com.

About The Sera Labs, Inc.

The Sera Labs, Inc. ("Sera Labs"), a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors with innovative products using cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories beauty, health & wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including opt-in subscriptions, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook and Instagram at @seratopical, as well as on X (Twitter) at @sera_ labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

Contacts:

Investor Relations
Hanover International Inc.
E: [email protected]
T: (760) 564-7400

SOURCE: Avenir Wellness Solutions, Inc.

C.Dean--TFWP